Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Income from Continuing Operations of 3140971.0 for Q1 2026, down 351.64% on a YoY basis from 1248184.0 in Q1 2025, and down 121.91% sequentially from 1415422.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Income from Continuing Operations data on file, last reported at 3140971.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 351.64% year-over-year to 3140971.0; the trailing twelve-month figure through Mar 2026 stood at 7240646.0 (down 119.88% YoY), and the FY2025 full-year result was 2851491.0, up 55.75% from the prior year.
- Income from Continuing Operations eased to 3140971.0 in Q1 2026, from 1415422.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1248184.0 in Q1 2025 to a low of 6301987.0 in Q4 2023.
- A 5-year average of 1436293.06 and a median of 1402433.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 1204.25% in 2024 and soared 165.61% in 2025, its largest moves.
- Tracing CPIX's Income from Continuing Operations over 5 years: stood at 2459714.0 in 2022, then sank by 156.21% to 6301987.0 in 2023, then soared by 69.82% to 1901637.0 in 2024, then rose by 25.57% to 1415422.0 in 2025, then sank by 121.91% to 3140971.0 in 2026.
- Business Quant data shows CPIX's Income from Continuing Operations at 3140971.0 in Q1 2026, 1415422.0 in Q4 2025, and 1949046.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -1.42 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -735,207.00 |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -6.30 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | 862,154.00 |
| Mar 31, 2023 | 172,286.00 |
| Dec 31, 2022 | -2.46 Mn |
| Sep 30, 2022 | -423,226.00 |
| Jun 30, 2022 | -1.36 Mn |
| Mar 31, 2022 | -1.40 Mn |
| Dec 31, 2021 | -4.39 Mn |
| Sep 30, 2021 | -1.58 Mn |
| Jun 30, 2021 | 724,684.00 |